CLINICAL TRIALS PROFILE FOR TRABECTEDIN
✉ Email this page to a colleague
All Clinical Trials for TRABECTEDIN
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00002904 ↗ | Ecteinascidin 743 in Treating Adults With Advanced Solid Tumors | Completed | European Organisation for Research and Treatment of Cancer - EORTC | Phase 1 | 1996-02-01 | RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of ecteinascidin 743 in treating adults with advanced solid tumors. |
NCT00003939 ↗ | Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma | Completed | European Organisation for Research and Treatment of Cancer - EORTC | Phase 2 | 1969-12-31 | RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of ecteinascidin 743 in treating patients who have advanced soft tissue sarcoma. |
NCT00005625 ↗ | Ecteinascidin 743 in Treating Patients With Previously Treated Metastatic Osteosarcoma | Completed | National Cancer Institute (NCI) | Phase 2 | 1999-12-01 | RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of ecteinascidin 743 in treating patients who have previously treated metastatic osteosarcoma. |
NCT00005625 ↗ | Ecteinascidin 743 in Treating Patients With Previously Treated Metastatic Osteosarcoma | Completed | Memorial Sloan Kettering Cancer Center | Phase 2 | 1999-12-01 | RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of ecteinascidin 743 in treating patients who have previously treated metastatic osteosarcoma. |
NCT00017030 ↗ | Ecteinascidin 743 in Treating Patients With Unresectable Advanced or Metastatic Soft Tissue Sarcoma | Completed | National Cancer Institute (NCI) | Phase 2 | 2001-02-01 | RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of ecteinascidin 743 in treating patients who have unresectable advanced or metastatic soft tissue sarcoma. |
NCT00017030 ↗ | Ecteinascidin 743 in Treating Patients With Unresectable Advanced or Metastatic Soft Tissue Sarcoma | Completed | Memorial Sloan Kettering Cancer Center | Phase 2 | 2001-02-01 | RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of ecteinascidin 743 in treating patients who have unresectable advanced or metastatic soft tissue sarcoma. |
NCT00027508 ↗ | Ecteinascidin 743 in Treating Patients With Malignant Mesothelioma | Terminated | National Cancer Institute (NCI) | Phase 2 | 2001-07-01 | RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of ecteinascidin 743 in treating patients who have malignant mesothelioma that cannot be removed by surgery. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for TRABECTEDIN
Condition Name
Clinical Trial Locations for TRABECTEDIN
Trials by Country
Clinical Trial Progress for TRABECTEDIN
Clinical Trial Phase
Clinical Trial Sponsors for TRABECTEDIN
Sponsor Name